Market Research Logo

Pharmaceuticals Market Research Reports & Industry Analysis

The pharmaceutical industry is directly impacted by the research conducted with prescription drugs, vaccines, and OTC drugs being manufactured based on findings from the study of life sciences. Clinical trials are conducted to ensure that products being developed are tested on how well they work on individuals affected by the diseases or conditions they are created to treat. The market research available can provide investors and analysts credible information on the direction of pharmaceuticals, anesthesia, drug delivery, pricing, regulations and policy being developed to ensure that knowledgeable and informed decisions are made regarding industry direction.
...Show More ...Show Less


Pharmaceuticals Industry Research & Market Reports

  • Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products

    ... filters) that prevent occurrence of nosocomial infections. Within each type of treatment, regional analyses will focus on the Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, ... Read More

  • Global Endocrinology Drugs Market 2018-2022

    ... Technavio’s analysts forecast the Global Endocrinology Drugs Market to grow at a CAGR of 6.48% during the period 2018-2022. Covered in this report The report covers the present scenario and the growth prospects of the ... Read More

  • Global Intragastric Balloons Market 2018-2022

    ... of food the stomach can hold and causes a feeling of fullness and satiety, which leads to less intake of food and resultant weight loss. Technavio’s analysts forecast the Global Intragastric Balloons Market to grow ... Read More

  • Pharmesis International Ltd (BFK) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • Morocco Pharmaceuticals & Healthcare Q4 2018

    ... treatments. Although the government'scommitment to improving healthcare via the expansion of health insurance coverage will be a significant factor for future medicinesales growth, we believe generics drugmakers will be the main beneficiaries as the state ... Read More

  • Nippon Kayaku Co Ltd (4272) - Financial and Strategic SWOT Analysis Review

    ... bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you ... Read More

  • MediciNova Inc (MNOV) - Financial and Strategic SWOT Analysis Review

    ... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More

  • Ipsen Biopharmaceuticals Inc - Strategic SWOT Analysis Review

    ... key employees, key competitors and major products and services. This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope ... Read More

  • Delcath Systems Inc (DCTH) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • Philippines Pharmaceuticals & Healthcare Q4 2018

    ... prominent theme within the Philippines pharmaceutical market, repressing drugmakersales growth. With the expansion of universal health coverage, these pressures will increase, offsetting the positive impact ofincreased access to services and a reduction in out-of-pocket payments. Read More

  • Colombia Pharmaceuticals & Healthcare Q4 2018

    ... Colombia. However, despite price control measures and a weak intellectual property environment, healthcarereforms and the rising burden of chronic diseases will facilitate the rising demand for medicines – boosting the consumption ofmedicines in volume terms. Read More

  • OPKO Health Inc (OPK) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • MDxHealth SA (MDXH) - Financial and Strategic SWOT Analysis Review

    ... you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand ... Read More

  • Achillion Pharmaceuticals Inc (ACHN) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • Catalyst Pharmaceuticals Inc (CPRX) - Financial and Strategic SWOT Analysis Review

    ... to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to ... Read More

  • Antipsychotic Drugs: Technologies and Global Markets

    ... a detailed analysis of the competitive environment, regulatory scenario, technological advancements, patent analysis, pipeline analysis, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2023, as well as market ... Read More

  • Kyrgyzstan Pharmaceuticals & Healthcare Q4 2018

    ... Kyrgyzstan's small and highly ruralised population will continue to restrict opportunities for multinational pharmaceuticalfirms. Key barriers for access to modern medicines include a lack of spending power and challenges in supply and distributionacross the country. Read More

  • Tanzania Pharmaceuticals & Healthcare Q4 2018

    ... limited by low per capita spending on medicines andan underdeveloped healthcare sector. Whilst demand for medicine will increase over the long-term, driven by the country’s rapidlyexpanding population and high disease burden, we expect that Tanzania's ... Read More

  • Santen Pharmaceutical Co Ltd (4536) - Financial and Strategic SWOT Analysis Review

    ... bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you ... Read More

  • Taro Pharmaceutical Industries Ltd (TARO) - Financial and Strategic SWOT Analysis Review

    ... bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you ... Read More

  • Spain Pharmaceuticals & Healthcare Q4 2018

    ... of the generic drug sector and the government’s continuedfocus on cost-containment measures targeting prescription drug expenditure. These trends, along with a subdued economicoutlook, make Spain one of the more challenging markets in Western Europe for ... Read More

  • Puerto Rico Pharmaceuticals & Healthcare Q4 2018

    ... targeting drug spending rise and the US administration maintainsa stringent stance towards securing federal healthcare funds for Puerto Rico. Economic challenges and outward migration of labourwill further raise risks to the island's attractiveness to manufacturers, ... Read More

  • Canada Pharmaceuticals & Healthcare Q4 2018

    ... environment maintains Canada's attractiveness for drugmakers,including opportunities to establish manufacturing facilities. However, drugmakers will be challenged by the increasing use ofaggressive pricing policies, with historically high generics prices increasingly becoming a target for cost-containment measures. Read More

  • Indonesia Pharmaceuticals & Healthcare Q4 2018

    ... health insurance scheme (JKN), further expansion will be hampered by deficit,investment shortages and uneven levels of healthcare access across the country. Additionally, for the pharmaceutical industry, theJKN's positive impact on growth is likely to wane ... Read More

  • Ethiopia Pharmaceuticals & Healthcare Q4 2018

    ... government is strongly committed to improvingthe operating environment to attract foreign investment, particularly from China, which combined with a budding manufacturingsector bodes well for foreign drugmaker appetite. Over the near-term, multinational drugmaker investment in the ... Read More

< prev 1 3 4 5 6 7 8 9 10